argenx SE
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ARGNF | ROIV | INCY | TGTX | BBIO | SRRK | |
|---|---|---|---|---|---|---|
| Market cap | 49.69B | 24.22B | 22.92B | 8.26B | 12.98B | 4.86B |
| P/E (TTM) | 30.1 | — | 14.4 | 19.6 | — | — |
| Forward P/E | — | -19.5 | 13.0 | 19.9 | -260.0 | -15.9 |
| Price/book | 5.9 | 5.7 | 3.6 | 12.7 | -5.2 | 19.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −5.20% | +89.01% | +31.22% | +53.67% | +18.02% | +42.91% |
| Today | 0.00% | −1.50% | −0.18% | −3.62% | −1.10% | −1.82% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ARGNF news ›Argenx Stops Phase 3 Vyvgart Trial in Sjögren's Disease After Monitors Find the Study Cannot Meet Its Goal
Argenx is ending a large Phase 3 study of its drug efgartigimod in Sjögren's disease after independent monitors concluded the trial cannot meet its main goal. The company announced the decision Oct. 8. An independent data monitoring…
What’s next for argenx, Europe’s autoimmune breakthrough?
European Biotechnology: What attracted you to the job at argenx? EB: You worked almost a decade at Roche’s Genentech before joining argenx. What’s the difference between working for a large pharma group and argenx? EB: Can you tell us…
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
Shares of Immunovant (IMVT) sold off Thursday as traders treated Argenx’s (ARGX) failed late-stage Sjögren’s trial as a warning for its own experimental drug for the autoimmune disorder. Immunovant (IMVT) fell about 6% to $30.06 in morning…
Analysts’ Top Healthcare Picks: Argenx Se (ARGX), Neurogene (NGNE)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Argenx Se (ARGX) and Neurogene (NGNE) with bullish sentiments. In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a…
argenx: The Sjögren's Selloff Looks Overdone
argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears to overstate the lost opportunity. Read more on ARGX stock here. - argenx shares fell after halting its Phase 3 Sjögren's trial, but the selloff appears…
Pharmalittle: We’re reading about a setback for Argenx, Lilly suits over copycat versions of an obesity drug, and more
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for more than three decades. His stories explore prescription drug pricing, affordability and access, as well issues surrounding…
argenx drops trial of efgartigimod SC in Sjögren's disease - The Pharma Letter
argenx drops trial of efgartigimod SC in Sjögren's disease The Pharma Letter
Argenx regains ground, Orange loses steam
Tryg jumps after better-than-expected results, while Argenx rebounds amid heavy volatility, supported by analysts. Modern Times Group plunges after the postponement of the IPO of its PlaySimple subsidiary, while Orange is hit by concerns…
Argenx falls as Sjögren’s setback offsets celiac drug progress
A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more “blockbuster expansion opportunity” for Vyvgart. The success of Vyvgart has propelled Argenx into the ranks of the world’s…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
-
theglobeandmail.com5
-
statnews.com3
-
stocktitan.net3
-
tradingview.com3
-
european-biotechnology.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 36 articles, not a forecast.